MedPath

PQ Bypass Guide Wire Delivery System for Femoropopliteal Bypass

Not Applicable
Completed
Conditions
Peripheral Arterial Disease
Registration Number
NCT01930071
Lead Sponsor
Endologix
Brief Summary

To assess the safety of performing a percutaneous fem-pop bypass using the PQ Bypass Guidewire Delivery System and commercially available stent grafts.

Detailed Description

Multi-center, single-arm first-in-man study utilizing the PQ Bypass Guide Wire Delivery System to access, deliver guidewires and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
4
Inclusion Criteria
  • Willing and able to provide informed consent

  • Age 18 or older

  • Rutherford Classification of 3-5

  • Lesions ≥10cm in length considered to be:

    • Chronic total occlusion (100% stenosis)
    • Diffuse stenosis (>50% stenosis) with moderate to heavy calcification
    • In-stent restenosis (>50% stenosis)
  • Proximal and distal target vessels are 4.8 - 7.5 mm in diameter

  • Orifice and proximal 1cm of SFA is patent

  • Patent popliteal artery 3cm proximal to tibial plateau

  • At least 1 patent tibial artery to the foot

  • Patent femoral vein

Exclusion Criteria
  • History of deep vein thrombosis
  • Has a known sensitivity or allergy to contrast materials that cannot be adequately pre-treated
  • Has a known sensitivity or allergy to aspirin, heparin or anti-platelet medications
  • Documented in-sensitivity to anti-platelet medication
  • Has a known or previous coagulopathy
  • Pregnant or lactating
  • Untreated flow-limiting aortoiliac occlusive disease
  • Has renal failure (GFR < 30mL/min)
  • Major distal amputation (above the transmetatarsal) in the study or non-study limb
  • Patient has had a procedure on the target limb within 30 days
  • Previous bypass surgery on the target limb
  • Bypass length required is greater than 35cm

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Primary Patency30 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Auckland City Hospital

🇳🇿

Auckland, New Zealand

Auckland City Hospital
🇳🇿Auckland, New Zealand

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.